Andere Sprachen Nexalin Technology, Inc.

Aktien

A3DFJP

US65345B2016

NXL

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 05.06.2024			% 5 Tage	% 1. Jan.
0,685 ^USD	-3,52 %		+1,53 %	+69,22 %

03.06.	Nexalin Technology, Inc. Nexalin Technology, Inc. gibt bekannt, dass die FDA ein Feedback und einen Konsens zum Design der geplanten klinischen Studien zu Angstzuständen und Schlaflosigkeit für das Gen-3 Halo Clarity Headset Gerät von Nexalin gegeben hat	CI
10.05.	Nexalin Technology, Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th	04.06.
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device	03.06.
Nexalin Technology, Inc. Announces FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 Halo Clarity Headset Device	03.06.
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts	22.05.
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10.05.
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23	09.05.
Nexalin Technology Regains Compliance With Nasdaq Listing Requirement	25.04.
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements	25.04.
Nexalin Technology : unveils positive results of clinical study for Gen-2 tACS device	18.04.
Nexalin Technology Files $5.6 Million Shelf Registration	16.04.
Nexalin Technology CEO Provides Letter to Shareholders	10.04.
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing	09.04.
Nexalin Technology Accelerates Manufacturing of Its HALO? Clarity Following Successful Usability, Feasibility, and Electrical Testing	09.04.
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device	04.04.
Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device	04.04.
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board	02.04.
Nexalin Technology, Inc. Announces the Appointment of William A. Hudson, Jr. to Military & Government Advisory Board	02.04.
Top Midday Gainers	28.03.
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego	28.03.
Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego	28.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Nexalin Technology, Inc.

Aktien

A3DFJP

US65345B2016

NXL

Andere Sprachen

Filter